-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 H/O15LBq0PZ4F3wsiUrSOP6JP+G0Nmu1wNcgdIfRkyoMTpIIn/HcEP43epUWbVEN
 3RCYLGYh8kaA88URxmmrEQ==

<SEC-DOCUMENT>0001102624-08-000194.txt : 20080804
<SEC-HEADER>0001102624-08-000194.hdr.sgml : 20080804
<ACCEPTANCE-DATETIME>20080804125445
ACCESSION NUMBER:		0001102624-08-000194
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080804
DATE AS OF CHANGE:		20080804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		08987273

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: August    04, 2008</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On August 4, 2008 ImmuCell Corporation (the "Company") issued a press release announcing earnings results for the three and six month periods ended June 30, 2008.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated August    04, 2008</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: August    04, 2008<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated August    04, 2008</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for the First Half of 2008</b>
<p>PORTLAND, ME -- 08/04/2008 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and six month periods
ended June 30, 2008.
</p>
<p>
For the three-month period ended June 30, 2008, product sales increased by
4%, or $35,000, to $826,000 in comparison to the same period in 2007.  For
the six-month period ended June 30, 2008, product sales increased by 7%, or
$157,000, to $2,457,000 in comparison to the same period in 2007.
</p>
<p>
"In this very challenging economic environment, we are gratified that our
customers have rewarded us with an 8% increase in sales our lead product,
First Defense&#174;, during the six-month period ended June 30, 2008,"
commented Michael F. Brigham, President and CEO.  "First Defense&#174; sales
continue to be seasonal with lower sales expected during the second and
third quarters."
</p>
<p>
Product development expenses increased by 44%, or $130,000, to $423,000
during the three-month period ended June 30, 2008 in comparison to the same
period in 2007.  Product development expenses increased by 35%, or
$195,000, to $755,000 during the six-month period ended June 30, 2008 in
comparison to the same period in 2007.
</p>
<p>
The net loss was $(238,000) (or $(0.08) per share) during the three-month
period ended June 30, 2008 in comparison to a net loss of $(60,000) (or
$(0.02) per share) during the same period in 2007. Technology licensing
revenue decreased by $158,000 (100%) and product development expenses
increased by $130,000 during the comparable periods.
</p>
<p>
The net loss was $(160,000) (or $(0.06) per share) during the six-month
period ended June 30, 2008 in contrast to net income of $237,000 (or $0.08
per diluted share) during the same period in 2007.  Technology licensing
revenue decreased by $316,000 (100%) and product development expenses
increased by $195,000 during the comparable periods.
</p>
<p>
"Our net loss reflects our strategic decision to make a significant and
controlled investment in the development of Mast Out&#174;, which entered into
its pivotal effectiveness trial during the second quarter," commented Dr.
Joseph H. Crabb, Vice President and Chief Scientific Officer.
</p>
<p>
Cash, cash equivalents and short-term investments increased by 5%, or
$283,000, to $5,695,000 at June 30, 2008 as compared to $5,412,000 at
December 31, 2007.  Stockholders' equity decreased by 1%, or $106,000, to
$9,951,000 at June 30, 2008 as compared to $10,057,000 at December 31,
2007.  The Company had 2,895,000 shares of common stock outstanding as of
June 30, 2008.
</p>
<p>
<pre>
                                         (Unaudited)       (Unaudited)
                                       Three Months Ended Six Months Ended
                                           June 30,          June 30,
                                        ----------------  ----------------
(In thousands, except per share
 amounts)                                 2008     2007     2008     2007
                                        -------  -------  -------  --------
Revenues:
Product Sales                           $   826  $   791  $ 2,457  $  2,300
Other Revenues                               --      168        5       335
                                        -------  -------  -------  --------
Total Revenues                              826      959    2,462     2,635

Cost and expenses:
Product costs                               447      511    1,261     1,141
Product development expenses                423      294      755       560
Selling, general and administrative
 expenses                                   351      307      772       656
                                        -------  -------  -------  --------
Total costs and expenses                  1,221    1,112    2,788     2,357
                                        -------  -------  -------  --------

Net operating (loss) income                (395)    (153)    (326)      278

Interest and other income                    56       70      116       146
                                        -------  -------  -------  --------

(Loss) income before income taxes          (339)     (83)    (210)      424
Income tax (benefit) expense               (101)     (23)     (50)      187
                                        -------  -------  -------  --------
Net (loss) income                       $  (238) $   (60) $  (160) $    237
                                        =======  =======  =======  ========

Net (loss) income per common share:
Basic                                   $ (0.08) $ (0.02) $ (0.06) $   0.08
Diluted                                 $ (0.08) $ (0.02) $ (0.06) $   0.08
                                        =======  =======  =======  ========

Weighted average common shares
 outstanding:
Basic                                     2,893    2,903    2,893     2,900
Diluted                                   2,893    2,903    2,893     3,066


                                          (Unaudited)
                                          At June 30,    At December 31,
(In thousands)                               2008             2007
                                        ---------------  ---------------
Cash, cash equivalents and short-term
 investments                            $         5,695  $         5,412
Total assets                                     10,302           10,412
Net working capital                               6,746            6,710
Stockholders' equity                    $         9,951  $        10,057
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
